Less recognized distinct regulatory mechanisms related to the enhancement of GLP-1 mediated action through the inhibition of phosphodiesterase enzymes (PDE) 4 has recently became a reasonable focus of a potential new anti-obesity management. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.